The Wayback Machine - https://web.archive.org/web/20130622140816/http://www.cnbc.com/id/100424502
 
Go Symbol Lookup
Loading...

Merck Earnings Beat, but Delays High-Profile Drug

 Text Size  
Published: Friday, 1 Feb 2013 | 4:06 PM ET
By: CNBC.com with Reuters
Merck | YouTube
Merck lab

Merck reported quarterly earnings that beat analysts' expectations on Friday, but it issued a cautious outlook and said it would delay seeking approval for a high-profile osteoporosis drug.

The company's shares closed down 3.28 percent Friday. (Click for latest quotes for Merck.)

The company posted fourth-quarter earnings excluding items of 83 cents per share, down from 97 cents a share in the year-earlier period.

Revenue decreased to $11.7 billion from $12.29 billion a year ago.

Analysts had expected the company to report earnings excluding items of 81 cents a share on $11.49 billion in revenue, according to a consensus estimate from Thomson Reuters.

Sales were helped by strong sales of its Januvia diabetes drug and Gardasil, a vaccine against cervical cancer.

However, the company said it was cautious for 2013's full-year profits. It said 2013 revenue would be near 2012 levels, on a constant currency basis.

Merck also said Friday it will not seek approval until next year for osteoporosis treatment odanacatib, a delay that Jefferies analyst Jeffrey Holford said ``will disappoint many investors.''

CEO Kenneth C. Frazier said the decision did not result from pressure from the U.S. Food and Drug Administration. He said the company continues to believe in the drug's potential and that the delay was necessary in order to include additional data from an extension trial.



 Print
The second-largest drugmaker in the U.S. said it earned 46 cents per share, compared with 49 cents per share in the same period a year ago.
  Price   Change %Change
MRK ---

   
Comments

 

More Comments

 
 

Add Comments

 

Your Comments (Up to 1100 characters):

Remaining characters

Your comments have not been posted yet.

Please review your submission to make sure you are comfortable with your entry.

Your Comments:


                
            
            
        

Featured